Monday, April 6, 2020

OncoSenX Developing New Gene Therapy Approach that Kills Cancer Cells by “Suicide”

Gene therapy faced many challenges in its early days, but scientific advances, drug approvals and millions in investment have accelerated research in the gene therapy field. WuXi AppTec Communications has begun a new series profiling some of the companies developing novel and...

Divide & Conquer Seeks to Disrupt Cell Communication in New Therapeutic Approach to Glioblastoma

WuXi AppTec Communications strives to find the latest cutting-edge technologies that can potentially offer new treatments for unmet medical diseases. Glioblastoma, a cancer of the brain, ranks high on the intractable disease list. A brand new biotech company, Divide...

Foghorn® Therapeutics’ Gene Traffic Control Product™ Platform: Regulating Gene Expression to Fight Intractable Disease

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) and WuXi AppTec Content Team One of the wonders of nature is how our DNA is compressed over a million times to fit into the nucleus of each...

Oncoceutics Hopes to Develop the First Effective Drug for High-Grade Glioma by Blocking Dopamine from Feeding the Deadly Cancer’s Growth

High-grade glioma is a deadly brain cancer with no effective long-term treatments, typically leaving children and adults with less than two years to live following diagnosis. Oncoceutics Inc. is tackling this challenge with a new investigational drug, ONC201, which...

Salarius Believes Children Should Not Be Left Behind in the Fight Against Cancer

Many pharmaceutical and biotech companies shy away from pediatric drug development. While the genomic revolution has resulted in scores of new cancer treatments for adults, children suffering from cancer have been left behind. It takes a spirit of determined commitment to real...

SUBSCRIBE TO OUR NEWSLETTER

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Reports Strong 2019 Annual Results

WuXi AppTec Reports Strong 2019 Annual Results Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted...